Cash Flow Statement

Amortizatization of Intangibles Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Receivables Depreciation & Amortization (CF)Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Other Working Capital Changes Share-based Compensation

Daily Values

Growth Metrics

Others

Ratios

Corvus Pharmaceuticals (CRVS) Net Income (2023 - 2025)

Historic Net Income for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q3 2025 value amounting to -$9.8 million.